Loading clinical trials...
Loading clinical trials...
To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of LP-005 in Healthy Volunteers
Conditions
Interventions
LP-005 Dose 1 (Single)
LP-005 Dose 2 (Single)
+9 more
Locations
1
China
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China
Start Date
November 23, 2023
Primary Completion Date
August 31, 2024
Completion Date
August 31, 2024
Last Updated
December 15, 2025
NCT05876312
NCT06312644
NCT03520647
NCT07152288
NCT07108023
NCT03056040
Lead Sponsor
Longbio Pharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions